‘Low-risk’ prostate cancer often not low-risk when targeted biopsy is used — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/05/140519084555.htm
source : http://www.sciencedaily.com/releases/2014/05/140519084555.htm
source : http://www.sciencedaily.com/releases/2014/03/140313134253.htm
source : http://www.sciencedaily.com/releases/2014/03/140307084000.htm
source : http://www.sciencedaily.com/releases/2014/02/140210135830.htm
The authors used a standard definition of overdiagnosis to refer to a cancer that would not have become symptomatic or clinically identifiable if it had not been detected by screening. Overdiagnosed cancers do not pose a risk to the patient and do not require treatment, which is associated with significant risks of impotence and incontinence. …
The study, published on Nov. 19, 2013, in the journal Clinical Cancer Research, adds long-term survival and safety data for the drug tasquinimod, a new candidate for treating advanced and recurrent prostate cancer. “While all subgroups in the clinical trial benefited from tasquinimod, those whose cancer metastasized to their bones had the greatest benefit in terms of delaying the time from the start of treatment to when the cancer progressed,” said lead author Andrew J…
In papers published in the American Journal of Public Health and the Bulletin of the History of Medicine, Aronowitz, professor and chair of Penn’s Department of History and Sociology of Science, characterizes the events then and screenings for prostate-specific antigen, or PSA, in more recent years as "part of one continuous story of how medical and lay people came to believe in the efficacy of population screening followed by aggressive treatment without solid supporting scientific evidence." "This is a call to reflection about how we deal with medical knowledge production and medical technological innovation," Aronowitz said. …
"The research of the circulating tumour cells (CTC) is of utmost importance, because nowadays there is no reliable marker of both cancer-specific or overall survival in castration-resistant prostate cancer (CRPC) patients," explained the lead author of the study, Dr. …
The reason is that the traditional prostate cancer screening test – a blood test to measure prostate specific antigen, or PSA – does not give doctors a complete picture. Now, the University of Michigan Health System has begun offering a new urine test called Mi-Prostate Score to improve on PSA screening for prostate cancer. …